Cosmetics Europe is preparing for challenges amid EU regulatory movement to clamp down on endocrine disruptors while also strategizing to defend CMR (carcinogenic, mutagenic or reprotoxic) substances within what could be a narrow timeframe for industry to build its case.
Cosmetics Europe Strategizing To Defend Ingredients Flagged As Endocrine Disruptors, CMRs
Clarification of requirements and a “demanding” timeline for industry’s defense of cosmetic ingredients identified as potentially carcinogenic, mutagenic or reprotoxic, and the Commission’s forthcoming list of potential endocrine disruptors in cosmetic products, are among challenges facing Cosmetics Europe in 2019 and beyond.
More from Europe
In response to an IPA Europe complaint, European Ombudsman Emily O’Reilly finds that the Commission’s interpretation of EU food legislation in relation to probiotics is “reasonable and in line with the main goal of this legislation, which is to ensure a high level of consumer protection.”
PAGB CEO Michelle Riddalls and ISF president emeritus David Webber have been awarded OBEs for their services to consumer health and self-care.
A recent Kenvue survey shows that an overwhelming majority of UK pharmacists believe many health issues could be prevented through better self-care.
Oral pseudoephedrine decongestants marketed by Kenuve, Haleon and Opella, amongst others, are now only available with a doctor's prescription in France.